Business & Regulation

Claudia Zylberberg reveals her career lessons learned and offers her perspective on the now booming advanced therapies industry.

The uncertainty surrounding the UK’s future with Europe is having a measurable effect on pharma. But it looks like the end is nowhere in sight.

Scientific careers are inherently unpredictable, but there are a number of steps we can take to be prepared.

The FDA has accepted TraceLink's blockchain and digital recall projects into its DSCSA Pilot Program.

Our animation explores the unique challenges a "no-deal" Brexit poses for the drug development and advanced therapy sectors.

We sit down with Nigel Theobald, Chief Executive, N4 Pharma. He tells us the story of his career and offers some advice for budding entrepreneurs.

Scouting for new leadership, prices hikes and successful acquisitions. What’s new for pharma in business?

Orphan drugs for rare diseases represent a significant unmet medical need for pharma, but commercialication can be tricky...

Nominations are now open for The Medicine Maker 2020 Power List.

How will the industry shape up over the next five years?